This editorial refers to 'Intracoronary autologous bone marrow cell transfer after myocardial infarction: the BOOST-2 randomised placebo-controlled clinical trial' † , by K.C. Wollert et al., on page 2936.
Non sunt multiplicanda entia sine necessitate Johannes Poncius, 1639 commentary on the works of Duns Scotus
Timely interventional coronary reperfusion is the single most important act that a cardiologist can perform to reverse dramatic consequences of the acutely occluded coronary artery associated with STsegment elevation myocardial infarction (STEMI). Progress in the standard of care with shortening of the ischaemic times as well as adjunctive pharmacotherapy yielded a profound impact on survival, myocardial salvage, and quality of life. 1 Nevertheless, despite timely reperfusion and global adoption of a 24/7 primary percutaneous coronary intervention (pPCI) service, the hospitalization rates for ischaemic cardiovascular events or heart failure still reach 14% with 6-to 12-month mortality rates ranging between 6% and 12%. 1, 2 In particular, patients with extensive post-infarct left ventricular (LV) dysfunction represent the population at risk, prone to develop overt heart failure, and could benefit from innovative strategies facilitating myocardial recovery.
Cell therapy as adjunct therapy in STEMI and evolving standards of care
Any innovative approach aiming to facilitate myocardial recovery after acute ischaemic injury, such as autologous bone marrow cell (BMC) therapy, competes against improving standards of guidelinebased therapies in STEMI patients, setting the bar high regarding the clinical impact and expectations if such a therapy were adopted. The current standard of care with widespread availability of pPCI, current drug-eluting stents, and antiplatelet medications, as well as high prescription of beta-blockers, angiotensin-converting enzyme inhibitors/ angiotensin receptor blockers, or aldosterone blockers, is clearly different as compared with the period of initial cell therapy trials 10-15 years ago. Unlike at that time, the risk of post-infarction heart failure is modified not only by reduced LV function but increasingly also by other factors such as ageing or co-morbidities. Overall, the adoption of cell therapy on top of the 2017 STEMI standard of care requires: (i) proof of efficacy on clinical endpoints or a clinically relevant surrogate; (ii) drug-like standardization of production and storage; (iii) understanding the mechanism of action; (iv) demonstration of periprocedural and long-term safety; and (v) approval by regulatory bodies throughout Europe. 3 Also, several other questions about practical implementation should be asked. BMC therapy requires bone marrow harvesting and cell production, followed by a second coronary catheterization associated with prolonged hospital stay. Would physicians be confident to recommend the second catheterization? Would the payer agree to cover such therapy, even if it has increased the ejection fraction (EF) by 5%, without data on long-term outcomes? What else would be needed to approve the therapy? All these factors should be taken into account when evaluating the current stage of autologous BMC therapy after STEMI. Over the last 15 years, numerous phase I and II studies explored adult BMC therapies as a post-STEMI adjunct. [4] [5] [6] [7] [8] [9] The clinical translation has been supported by the notion that adult stem and progenitor cells participate in myocardial repair, as well as by early pre-clinical studies demonstrating the benefits on myocardial remodelling and function in various animal models. 4 In contrast to initial enthusiasm sparked by early 
BOOST programme and its results
The BOOST programme was initiated under the leadership of the late Helmut Drexler 15 years ago with the first randomized study on cell therapy after STEMI. 9 Using the state-of-the-art magnetic resonance imaging (MRI) evaluation and open-label design, initial results of BOOST showed an early significant improvement in LVEF after BMC therapy. 8 Despite the later observations that the benefit on cardiac function wore off at long-term follow-up, 9 Wollert and colleagues aimed to re-evaluate the therapeutic potential of nucleated BMCs on MRI-derived LVEF in a randomized, double-blind placebo-controlled study. Published in this issue, 10 BOOST-2 has been designed as a randomized, multi-arm and double-blind placebo-controlled study addressing pertinent unknowns of the cell therapy. Importantly, the investigators used the broader population of total nucleated BMCs rather than the mononuclear fraction (MNC) as an active biologic. For the first time, they aimed to investigate the mechanism of action and address the dose dependency in the clinical setting. To decode the paracrine effect vs. other putative factors (clonogenic/transdifferentiation) of nucleated BMCs, the BOOST-2 investigators compared fully competent vs. c-irradiated cells devoid of colony-forming unit capability. The cells were well characterized, with preserved functional potency as evidenced by relevant functional assays, and the standardized protocol of cell separation was identical to that in the initial BOOST trial (gelatine-polysuccinate density gradient sedimentation). Disappointingly, the trial failed to show an improvement in LVEF fraction and did not meet any other secondary MRI endpoints. Likewise, there was no signal of the efficacy of fully competent cells compared with c-irradiated cells or signals of a dose-dependent effect.
Implications of the BOOST-2 programme
The negative outcome of such a well-designed trial is disappointing. However, as alluded to earlier, it should be placed into the perspective of similar trials testing adjunctive approaches in STEMI 2 and the current landscape of advanced standard of care. It should also be noted that even in the very experienced centres actively pursuing this trial, the projected sample size could not be reached and the trial was stopped prematurely. Slow enrolment is another 'silent' warning that perhaps the clinical need, at least as reflected in clinical follow-up surveillance in the population selected by the BOOST-2 trial, is not as high as one expects from the reported morbidity/mortality statistics. 1, 2 It is consistent with the inclusion of the relatively low-risk population as reflected by a high proportion of patients with moderately reduced LVEF at baseline with low morbidity, heart failure progression, or implantable cardioverter defibrillator implantation at 6 months follow-up. The negative outcome of such a well-designed and rigorously executed study as BOOST-2 will undoubtedly diminish the enthusiasm of other investigators to continue similar studies. Overall, BOOST-2, as presented in this issue, is closing series of trials with MRI readouts with no benefits on cardiac structure and function in the STEMI setting. Perhaps the principle of Ockham's razor should be accepted, favouring the simplest answer and avoiding multiplying the entities beyond necessity. The neutral results indeed converge to the conclusion that despite a strong biologic rationale, current BMC therapy may simply not be effective in STEMI, at least regarding improvement in cardiac function.
Nevertheless, before making this call, we should follow the principles of scientific thoroughness and await the outcome of the European Commission-funded BAMI project. 11 The BAMI project extends the rigorous translational and clinical REPAIR-AMI programme that yields standardized, functionally superior cell biologics as compared with other cell therapy trials with bone marrowderived MNCs. 5, 12 The comparison of REPAIR-AMI/BAMI and BOOST-2 is difficult because the number of cells is greater (20.6 ± 7.7 Â 10 8 nucleated cells) and BAMI includes patients with more depressed LV function. It is also tempting to speculate that use of a heparin-free cell production environment is superior based on the mechanistic studies on disrupted stromal cell-derived factor 1 (SDF-1)-mediated migration. 12 Thus, the results of the BAMI trial are much awaited by the scientific community despite the delay in its initiation after promising 2006 results of the phase II REPAIR-AMI trial. 5 BAMI findings and its deliverables are likely to provide the final call on intracoronary cell therapy as a biologic adjunct early after STEMI.
Landscape after BOOST-2
How would late Helmut Drexler, as a thoughtful and forwardlooking clinical scientist, act knowing the previous unknowns? The imperative of every negative setback is to refocus and redefine the next objectives and hypotheses. Cell therapy should be focusing on defining its place in multidisciplinary heart failure management including other emerging biologics or device-based approaches. If the cell therapy is to be adopted within the current armamentarium of standard of care, it should provide compelling translational and clinical evidence on myocardial repair halting the progression of LV dysfunction and heart failure 3,13 ( Figure 1 ).
Several translational and clinical research programmes are advancing the knowledge on mechanisms of action and strategies boosting the potency of reparative biologics. In this regard, the work of the BOOST investigators on the analysis of the proteome of BMCs and identification of potential regenerative paracrine factors should be applauded.
14 They showcase an example of an acellular next-generation regenerative strategy. Other examples include next-generation products of expanded multicellular or lineage-specified products as well as bioengineered or combined approaches. 3, 13, 15 Together with optimization of delivery strategies and definition of the optimal therapeutic window of the target population, they strive to boost reproducible and effective myocardial repair ( Figure 1 ).
Conclusion
Intracoronary cell therapy to date is not meeting the over-reaching expectations from the early 2000s. We should acknowledge that 
